Alma Lasers
One connected operating model across the wellness ecosystem
- Aesthetic Medical Devices
- Caesarea, Israel
- January 2026
A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Alma Lasers's published strategy and is not endorsed by, or produced in cooperation with, Alma Lasers. Company website
Strategic priorities
Alma Lasers, the energy-based devices subsidiary of Sisram Medical, is in the middle of a strategic shift from selling capital hardware to running an integrated wellness ecosystem that combines laser and light-based platforms, injectables such as DAXXIFY and Profhilo, the Copulla digital-dentistry workflow, and home-use devices. The company is dual-headquartered in operation: innovation and R&D in Caesarea, Israel, and a growing manufacturing and pharmaceutical footprint in Haikou and Tianjin, China. Revenue from direct sales reached 87 percent of the total in 2024, up from 66 percent two years earlier.
The 2025 numbers make the operational pressure visible. Sisram's gross margin moved from 62.4 percent to 60.0 percent in the first half, and management cited inventory accumulation as a deliberate response to supply-chain uncertainty. H1 2025 also saw the Injectables segment accelerate as DAXXIFY cleared its final regulatory step for the China market, and the third-quarter 2025 update described momentum across the core businesses.
The Israeli operations and the new Chinese sites now need to behave as one operating model rather than two parallel ones. NetSuite has unified finance and sales, but the shop-floor and clinical data layers still sit in the same disconnected state the company described before its ERP migration. Closing that gap is the practical condition for the ecosystem strategy to work at the volume management is now planning for.
Copulla, the digital-dentistry platform intended to be the workflow disruptor for the segment, is still being described in public filings as a pilot, with revenue contracting on the back of what management calls demand pressure on a pre-mature business. Building the underlying orchestration so Copulla can move from tens of clinics to thousands is a separate piece of work from the supply-chain and quality initiatives above it.
-
01
Energy-based devices remain the revenue base
Soprano Titanium, Harmony, Opus and the rest of the energy-based devices portfolio still produced the majority of 2024 revenue. The move to AI-assisted treatments and the Smart Clinic concept is the company's bid to defend that base against hardware commoditisation.
-
02
Injectables as the second growth engine
Distribution of DAXXIFY (long-lasting botulinum toxin) and Profhilo (bioremodeling) gives the group a recurring consumables stream. The Haikou facility underpins this and brings pharmaceutical-grade regulatory expectations into the group for the first time.
-
03
Digital dentistry through Copulla
Copulla is positioned as an end-to-end scan-to-delivery workflow for dental clinics. Sisram's 2024 interim report describes the segment as pre-mature, with the pilot still being evaluated for the path to commercialisation.
-
04
A closed-loop Chinese value chain
The China strategy integrates local R&D, manufacturing and commercialisation to serve the APAC market and to qualify for local procurement policies. This is the source of the bifurcated supply chain the rest of the operating model has to reconcile with.
Challenges we see
- Operations Supply Chain
Reading inventory position across two manufacturing regions
Alma's Israeli operations and its Chinese manufacturing and distribution hubs are run as parallel inventories. Sisram's H1 2025 results explicitly cited an increase in inventory to face supply-chain challenges, and gross margin moved from 62.4 percent to 60.0 percent in the same period.
When each region holds inventory to protect itself from the other, the buffer the company carries grows with the distance between the two, and capital that could fund new products stays locked in stock.
- Digital Integration
Connecting the shop floor to the enterprise system
The NetSuite migration unified finance and sales after a period in which each subsidiary was running its own system, with disjointed data and limited visibility into stock. The production and service layers were not part of that consolidation, and a Haikou facility is now coming online without the same level of integration.
Where the manufacturing execution layer stays separate from the new enterprise system, the data the business uses to make decisions is reconstructed after the fact rather than observed as it is generated.
- Quality Manufacturing
Holding a single quality standard across both regions
The Israel-Quality brand premium is part of how Alma prices its devices. Manufacturing in China is scaling to meet volume, and the test data from the Chinese sites does not currently reach the Israeli engineering teams in a form that supports automatic comparison.
When acceptance criteria for a device are set in one location and verified manually in another, the conversation about whether a batch is good depends on a paper comparison rather than a shared reference.
- Digital Integration
Building the digital dentistry platform to a commercial scale
Copulla's 2024 interim report described a successful pilot and an evaluation of the path to commercialisation, with revenue contracting on what management called demand pressure on a pre-mature segment. The workflow still relies on manual coordination of scan intake, design routing, manufacturing ticketing and patient-specific tracking.
An orchestration layer that turns scan, design and production steps into an automated sequence is what makes the difference between a workflow that a small concierge team can run and one that survives a thousand clinics.
- Compliance Regulatory
Meeting pharmaceutical data-integrity expectations at the Haikou site
DAXXIFY cleared its final regulatory step for the China market in 2025, and the Haikou facility is where the biologic is being produced. Pharmaceutical production carries GxP data-integrity requirements under ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring and Available) that are a step change from the documentation practices typical in laser manufacturing.
Where manufacturing records exist on paper and a regulatory inspection asks for the history of a vial, the answer has to be reconstructed from signatures and travel sheets rather than read from a system that captured the events as they happened.
Opportunities, by urgency and business impact
Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.
-
Building a control-tower view of inventory across regions
Israeli and Chinese operations currently each hold their own safety stock. Sisram's H1 2025 results explicitly cited inventory accumulation and a 240 basis point gross-margin decline over the prior-year period.
A control-tower layer that aggregates inventory, demand and supply signals from Caesarea, Haikou, Tianjin and the global distribution hubs lets safety stock be set from a system view rather than a regional view, and frees working capital that currently sits in buffer.
- Sisram Medical Reports First-Half 2025 Results, August 2025
- Sisram Medical Announces 2024 Annual Results, March 2025
-
Capturing test data at the line in both regions
Acceptance data from the Chinese assembly and test stations does not currently flow automatically to the Israeli engineering reference, and reference parameters from Israel do not currently travel back as executable acceptance criteria.
Instrumenting test benches in both regions and routing their results to a shared reference set turns the cross-site quality conversation into a system comparison and shortens the path from an out-of-tolerance reading to a quality hold.
- Alma Lasers Gets a NetSuite Makeover, Enterprise Times, 2021
- Sisram Medical H1 2025 Results, August 2025
-
Turning device connectivity into a service signal
Customer reviews describe technicians arriving without the parts needed to complete a service call, and parts sitting on backorder until a fixed future date. The hardware is sold as connected, but the connectivity is not yet a service signal.
Streaming selected console health indicators — flashlamp voltage, pump rotation, diode temperature — into a service model and using it to trigger parts orders and dispatch produces an uptime outcome the customer can be sold a guarantee on.
- Sisram Medical 2024 Annual Results, March 2025
- Consumer review patterns referenced in the deep-research file
-
Automating the Copulla scan-to-delivery workflow
The Copulla dental division is described in the 2024 interim report as a pre-mature segment in pilot, with revenue contracting on demand pressure. The orchestration between intra-oral scanning, design routing, manufacturing ticketing and patient delivery is largely manual.
Replacing the manual orchestration with a cloud workflow that ingests scans, routes designs on capacity and specialisation, and issues production jobs automatically gives Copulla a path from a small number of pilot clinics to the volume its commercial case depends on.
- Sisram Medical 2024 Interim Report, September 2024
-
Putting Haikou biologics production on a validated digital record
The Haikou facility is producing DAXXIFY under pharmaceutical data-integrity expectations, and the site's production and quality records are still paper-based in places. The 2025 warning letter to a peer in the aesthetic-laser sector signals the level of attention being paid to management review and QMS (Quality Management System) effectiveness.
A validated stack combining a LIMS (Laboratory Information Management System) for QC (Quality Control) data, electronic batch records in place of paper travel sheets, and per-vial serialisation for cold-chain verification makes the regulatory evidence continuous rather than assembled at audit time.
- FDA warning letter to Technological Medical Advancements LLC, September 2025
- Sisram Medical clears final regulatory step for DAXXIFY market entry in China, BioPharma APAC, 2025
What we'd propose
- Enterprise AI
Supply-chain control tower for the Israeli and Chinese operations
An end-to-end supply-chain visibility layer that aggregates inventory, demand and supply signals from Caesarea, Haikou, Tianjin and the global distribution hubs, and that uses those signals to set safety stock from a system view rather than a regional one.
-
Cross-region inventory aggregation
Pull inventory and in-transit positions from each region's ERP and warehouse systems into a single model, with currency, unit-of-measure and lead-time normalisation applied at the boundary so the numbers can be compared on the same basis.
-
Demand-driven safety stock
Use historical sell-through, service-level targets and supplier lead times to compute safety stock per SKU (stock-keeping unit) and per region, replacing the fixed buffer with a number the business can defend in front of finance and operations.
-
Exception workflow
When a forecast, lead time or stock position moves out of tolerance, route the exception to the named owner in the region that can act on it, with the supporting numbers attached so the conversation starts from data rather than recollection.
- Working capital released from regional safety stock supports the same service level at a lower inventory number.
- Finance, operations and commercial teams read the same picture instead of reconciling three regional extracts.
- Service events that originate in supply gaps become visible before they reach the customer.
-
- Digital CDMO
Cross-region quality tether between Israeli engineering and Chinese production
An IoT (Internet of Things) layer on the test benches in both regions, feeding a shared reference of acceptance parameters so the conversation about whether a batch is acceptable becomes a system comparison rather than a paper comparison.
-
Reference parameter capture in Israel
Capture pulse duration, energy stability, cooling curve and other critical parameters from validated Israeli test runs as the reference set, with the data captured at the bench rather than re-entered into a spreadsheet.
-
Test data capture in China
Run the same parameter capture on the Chinese test benches, with the results written directly into the shared model so a cross-region comparison is a query, not a manual transfer.
-
Deviation and SPC (statistical process control) view
Surface drift against the reference set and statistical-process-control charts across both regions, so a quality issue in one site is visible to engineering in the other before it becomes a finished-goods investigation.
- A single acceptance reference is owned by the engineering team, not by whichever site runs the test.
- A cross-region deviation shows up as a system event rather than as a finding in a retrospective report.
- The quality story in front of a regulator is the same on both sides of the value chain.
-
- Digital CDMO
Connected-service platform on the Soprano and Harmony consoles
A service layer on the installed base that streams selected console health indicators into a service model, and uses the model to trigger parts orders and dispatch before a service event reaches the customer.
-
Console telemetry
Capture flashlamp voltage, cooling-pump rotation, diode temperature and similar indicators at a cadence that supports trending without producing data the service team has no time to read.
-
Predictive service model
Run a service model against the captured stream that identifies a console approaching a service condition and produces a service ticket before the call comes in from the clinic.
-
Parts and dispatch integration
Trigger a parts reservation in the service-supply chain and a dispatch instruction to the technician that names the parts the visit will need, so the technician arrives with what the visit requires.
- Backorder and repeat-visit complaints become the exception rather than a known cost of doing business.
- Service becomes a commercial asset the company can sell against, rather than a cost centre it has to absorb.
- Engineering sees how the installed base is actually behaving once the field signal is in.
-
- Digital Lab
Copulla workflow engine for scan-to-delivery
A cloud workflow that ingests intra-oral scans, routes designs on capacity and specialisation, and issues production jobs automatically so Copulla can serve a thousand clinics without a thousand coordinators.
-
Multi-vendor scan ingestion
Ingest scans from the main intra-oral scanner families (3Shape, iTero, Planmeca and others) into a single canonical format so the workflow starts from one shape of evidence, regardless of what the clinic already owns.
-
Design routing
Route each case to a design team based on capacity, specialisation and committed turnaround, with the routing decision visible to the clinic so the timeline is honest.
-
Production and delivery tracking
Issue a production job to the manufacturing centre with material and patient-specific parameters captured once and reused downstream, and track the case through to patient delivery so a clinic can answer its own patient without calling in.
- Copulla moves from a small pilot to the volume its commercial case requires, on the same headcount.
- Each step in the workflow leaves a digital trace the service team can read, so a stalled case is visible before the clinic asks about it.
- A multi-vendor clinic does not have to change its scanner to use the platform.
-
- Agents
Agents for the regulatory and clinical document load
Narrow, reviewable agents that take the recurring part of regulatory and clinical document work — drafting MDR (European Medical Device Regulation) and multi-region submissions (FDA 510(k), CE-MDR, NMPA, PMDA) from source records, checking a document against its template before review, and tracing every controlled document a standards change affects — with a named reviewer approving every output.
-
Drafting from source records
Generate the first draft of a clinical-evaluation report, a 510(k) section, a post-market surveillance update or a periodic safety report from the underlying system records, so the author edits and judges rather than assembles.
-
Template and completeness checking
Check a document against the template and the checklist the regulator or internal SOP (standard operating procedure) requires, returning missing or inconsistent sections before the document enters the human review queue.
-
Change impact across the document set
When a standard, harmonised rule or internal procedure changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one.
- Submissions across FDA 510(k), CE-MDR, NMPA and PMDA (Japan) are produced from the same underlying evidence with a region-specific surface.
- Review queues move faster because documents arrive complete, with the source records attached.
- The scope of a standards change is established by search, not by recollection.
-
Digital maturity: today and target
Scored out of 100 across six dimensions. The target is what Alma Lasers's own published ambition implies — not a perfect score.
- Supply chain digitalization 38 → 80
- NetSuite unified finance and sales. Inventory, in-transit and supplier data still sit in regional systems, and the 2025 results point to that gap through the deliberate inventory build and the margin movement.
- IT/OT integration 32 → 75
- The ERP layer is now common. The shop floor in Israel and the new Haikou facility are not yet connected to it in a way that supports real-time decisions, and the engineering teams describe the same pre-migration state of disjointed data in the operations layer.
- Cross-region quality systems 42 → 80
- Israeli quality is a stated brand promise. Chinese manufacturing is scaling without a shared reference for acceptance parameters, which means the conversation about a batch is paper-based rather than system-based.
- Connected device service 40 → 78
- Devices are sold as connected. The service signal is not yet a useful input into parts and dispatch, and the customer experience still includes backorders and repeat visits.
- Digital workflow scale-up 28 → 72
- Copulla's 2024 interim report describes a pre-mature segment in pilot. The workflow remains a manual coordination of scan, design and production rather than an automated sequence.
- Pharmaceutical data integrity 30 → 80
- DAXXIFY is being produced in a facility that has to meet ALCOA+ data-integrity expectations. The current state is closer to laser-manufacturing documentation than to validated pharmaceutical records, and the gap is visible in the 2025 regulatory signal in the broader aesthetic-laser sector.
Check this yourself
Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.
-
Self-assessment
Data & AI Maturity
See how ready your data actually is for the AI work you're planning.
-
Self-assessment
Electronic Batch Record (eBR) Readiness
Check how far your batch records are from paperless, and what the next step is.
-
Market comparison
Pharma Data Platform Use Cases — Ranked
Use cases ranked by how hard they are against what they're worth.
-
Market comparison
European CDMOs Compared
The 2026 landscape: who does what, at what scale.
Think we've read this right?
Talk to usRelated reading
-
OPC UA protocol support in embedded systems
OPC Unified Architecture (OPC UA) is a modern standard for data exchange, increasingly used in industrial environments.
-
From Paper to Performance: Operational Efficiency and Compliance in Labs
Transform your QC lab with scalable digital solutions that embed compliance, boost efficiency, and deliver a future-ready competitive edge.
-
Maximizing Competitiveness in the age of Automation
In today's widespread industrial process automation, companies often face the question of how to maximize profits. There are many answers...
-
Don’t let vendor lock-in hold your lab hostage.
How biotech labs avoid vendor lock-in by extending SCADA capabilities with flexible control platforms and multi-vendor integration.
-
From Adoption to Redesign: What 12 Agentic-AI Reports Reveal
88% of companies use AI. Only ~6% capture real profit from it. Twelve major 2025–26 reports agree on why — redesign, not tooling, separates the winners.
This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Alma Lasers, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].